Attack Of The Hair Restoration Robot

Robots invaded the operating room years ago, providing surgeons with high precision tools to perform a wide range of procedures from prostatectomies to partial knee replacements. Now, Restoration Robotics is hoping to take over the private practices of hair restoration surgeons. Last year, the venture-backed company launched ARTAS, a robotic system capable of minimally invasive removal of hair follicles used in hair transplants. Restoration Robotics executives see ARTAS as a way to level the playing field between hair restoration surgeons who are capable of performing the sometimes tricky follicular unit extraction and those who want to offer the procedure but don’t have the skills or resources. By conservative estimates, FUE accounts for less than 20% of the $1 billion hair restoration industry. Restoration Robotics sees its robotic system enabling more surgeons to perform FUEs, which could convince more prospective patients to undergo a hair restoration procedure.

Doug Kelly gave new meaning to the colloquialism “putting your own skin in the game.” The phrase normally applies to an investor willing to risk his or her own money as a clear vote of confidence in a company with a still undetermined future. However Kelly, general partner at Alloy Ventures, put his actual skin into the game in December. Bald most of his adult life, Kelly chose to undergo a hair transplant procedure using the ARTAS system, the robotic hair retrieval system manufactured by Restoration Robotics Inc., one of his own portfolio companies. Kelly never was comfortable with his baldness, but he was less comfortable with the surgical options available to remedy it. His decision to undergo the procedure using the ARTAS robot only happened because he had confidence that the new device could reliably produce the result he wanted.

Kelly’s change of heart is an early indicator of a robotic revolution Restoration Robotics might be bringing to the aesthetics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By 

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

More from In Vivo

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By 

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By 

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.